VeracyteVCYT -4.63%75 Receivables Turnover is 2.93 as of Mar. 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.19 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Veracyte ranks better than 87.62% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Veracyte's Revenue for the
three
months ended in Mar. 2026 was $139.1 Mil. Veracyte's average Accounts Receivable for the
three
months ended in Mar. 2026 was $47.4 Mil.
Hence, Veracyte's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.93.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Veracyte Receivables Turnover Related Terms
Veracyte Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Veracyte's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCYT vs RDNT, SHC, BLLN: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Veracyte's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Veracyte's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a Receivables Turnover of 2.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Veracyte and its competitors. According to the industry distribution chart, Veracyte ranks #25 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 12.4%.
Is Veracyte's Receivables Turnover too high?
Veracyte's current Receivables Turnover is 2.93. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Veracyte's value of 2.93 is 45.7% below this industry median. Based on the distribution chart, Veracyte ranks #25 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Receivables Turnover compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #25 out of 202 companies for Receivables Turnover. This places Veracyte in the top 12% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.40. Veracyte's value of 2.93 is 45.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current Receivables Turnover of 2.93 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current Receivables Turnover is 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.19, compared to a current price of $57.10 — trading 49.5% above its estimated fair value. The current Receivables Turnover is 2.93 and 45.7% below the Medical Diagnostics & Research industry median of 5.40. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Veracyte (VCYT), the current Receivables Turnover is 2.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $57.10 is trading 49.5% above its estimated GF Value™ of $38.19.
GuruFocus considers Veracyte to be Significantly Overvalued.
Key valuation signals for VCYT:
Receivables Turnover: 2.93
GF Value™: $38.19 vs. price of $57.10 (49.5% above fair value)
Industry Position: 45.7% below the Medical Diagnostics & Research median (#25 of 202)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score
Get the complete analysis for VCYT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
